Actively Recruiting
Randomized Study of GSK5784283 Compared With Placebo in Adults 40 to 80 Years With Moderate to Very Severe COPD
Led by GlaxoSmithKline · Updated on 2026-09-09
624
Participants Needed
2
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug GSK5784283 Felcorekibart as an additional treatment compared to placebo for adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. The study aims to demonstrate that GSK5784283 reduces the annual rate of moderate and severe COPD flare-ups. This Phase 3, randomized, double-blind trial includes participants who have an eosinophilic phenotype and frequent exacerbations despite standard COPD therapy. Participants are randomly assigned to receive either GSK5784283 plus standard care or a matching placebo plus standard care. Both groups continue their usual COPD treatments, which may include triple or dual inhaled therapies. The study lasts up to 78 weeks, during which the main focus is on the frequency of COPD exacerbations. Secondary measures include changes in lung function, respiratory health questionnaires, and rates of exacerbations requiring emergency care or hospitalization. During the trial, participants will have regular assessments including spirometry to measure lung function, questionnaires about respiratory health, and monitoring of COPD exacerbations and related hospital visits. Blood tests will identify eosinophil counts to understand treatment effects on specific patient groups. The study team will closely monitor safety and track all outcomes up to the end of the 78-week period, with overall participation lasting until study completion around March 2030.
CONDITIONS
Brief Title
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here